[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100552451":3},{"organization":4,"armGroups":7,"interventions":32,"overallOfficials":10,"centralContacts":63,"locations":69,"responsibleParty":120,"collaborators":10,"id":122,"slug":123,"hasResults":124,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":128,"eligibilityCriteria":129,"healthyVolunteers":124,"sex":130,"minAge":10,"maxAge":10,"enrollmentInfo":131,"targetDuration":134,"studyType":135,"phases":10,"briefSummary":136,"conditions":137,"keywords":10,"overallStatus":72,"whyStopped":10,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":150},{"fullName":5,"class":6},"Santa Chiara Hospital","OTHER",[8,15,22,27],{"label":9,"type":10,"description":11,"interventionNames":12},"ADT + docetaxel",null,"mHSPC patients treated with ADT + docetaxel",[13,14],"Drug: Docetaxel","Drug: Triptorelin",{"label":16,"type":10,"description":17,"interventionNames":18},"ADT + ARPI","mHSPC patients treated with ADT + ARPI",[19,20,21,14],"Drug: Apalutamide Oral Tablet","Drug: Enzalutamide Oral Tablet","Drug: Abiraterone acetate tablets",{"label":23,"type":10,"description":24,"interventionNames":25},"ADT + ARPI + docetaxel","mHSPC patients treated with ADT + docetaxel + ARPI",[13,26,14],"Drug: Darolutamide Oral Tablet",{"label":28,"type":10,"description":29,"interventionNames":30},"ADT + radiotherapy on primary tumor","mHSPC patients treated with ADT + radiotherapy on primary tumor",[31,14],"Radiation: radiotherapy",[33,38,42,46,50,54,59],{"type":34,"name":35,"description":36,"armGroupLabels":37,"otherNames":10},"DRUG","Docetaxel","6 courses of docetaxel 75 mg\u002Fsqm iv",[23,9],{"type":34,"name":39,"description":40,"armGroupLabels":41,"otherNames":10},"Apalutamide Oral Tablet","240 mg \u002Fdaily orally",[16],{"type":34,"name":43,"description":44,"armGroupLabels":45,"otherNames":10},"Enzalutamide Oral Tablet","600 mg \u002Fdaily orally",[16],{"type":34,"name":47,"description":48,"armGroupLabels":49,"otherNames":10},"Abiraterone acetate tablets","1000 mg \u002Fdaily orally",[16],{"type":34,"name":51,"description":52,"armGroupLabels":53,"otherNames":10},"Darolutamide Oral Tablet","600 mg\u002Fdaily orally",[23],{"type":55,"name":56,"description":57,"armGroupLabels":58,"otherNames":10},"RADIATION","radiotherapy","radical radiotherapy on primary tumor",[28],{"type":34,"name":60,"description":61,"armGroupLabels":62,"otherNames":10},"Triptorelin","3,75 mg im\u002F4 w",[16,23,9,28],[64],{"name":65,"role":66,"phone":67,"phoneExt":10,"email":68},"Orazio Caffo, MD","CONTACT","+390461904416","orazio.caffo@apss.tn.it",[70,91,107],{"facility":71,"status":72,"city":73,"state":74,"zip":75,"country":76,"countryCode":77,"cosmosGeoPoint":78,"geoPoint":83,"contacts":84},"Azienda Ospedaliera San Luigi","RECRUITING","Orbassano","Torino","10043","Italy","IT",{"type":79,"coordinates":80},"Point",[81,82],7.53813,45.00547,{"lat":82,"lon":81},[85,89],{"name":86,"role":66,"phone":87,"phoneExt":10,"email":88},"Consuelo Buttigliero, MD, PhD","+390116705492","consuelo.buttigliero@unito.it",{"name":86,"role":90,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"facility":92,"status":72,"city":93,"state":10,"zip":94,"country":76,"countryCode":77,"cosmosGeoPoint":95,"geoPoint":99,"contacts":100},"Istituto Oncologico Veneto","Padova","35128",{"type":79,"coordinates":96},[97,98],11.14261,44.38225,{"lat":98,"lon":97},[101,105],{"name":102,"role":66,"phone":103,"phoneExt":10,"email":104},"Umberto Basso, MD","+39-049-8215953","umberto.basso@iov.veneto.it",{"name":106,"role":90,"phone":10,"phoneExt":10,"email":10},"Basso Umberto",{"facility":5,"status":72,"city":108,"state":10,"zip":109,"country":76,"countryCode":77,"cosmosGeoPoint":110,"geoPoint":114,"contacts":115},"Trento","38122",{"type":79,"coordinates":111},[112,113],11.12108,46.06787,{"lat":113,"lon":112},[116,118],{"name":65,"role":66,"phone":117,"phoneExt":10,"email":68},"+39 046190212",{"name":119,"role":90,"phone":10,"phoneExt":10,"email":10},"Orazio Caffo",{"type":90,"investigatorFullName":119,"investigatorTitle":121,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Director","100552451","evaluation-of-clinical-outcomes-of-chemotherapy-or-androgen-receptor-targeting-agent-alone-or-combined-or-radiotherapy-on-primary-tumor-in-addition-to-androgen-deprivation-therapy-in-hormone-sensitive-metastatic-prostate-cancer-patients-100552451",false,"NCT06473259","Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients","Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Therapy (Alone or in Combination) or Radiotherapy on the Primary Tumor in Combination With Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: Multicenter Observational Study of Patients Undergoing Treatment in Clinical Practice in Italian Hospitals","ECHOS","Inclusion Criteria:\n\n1. histologically confirmed diagnosis of adenocarcinoma of the prostate, metastatic, not undergoing previous treatment (except hormone therapy initiated no more than 4-6 months prior to docetaxel) for metastatic disease\n2. treatment with docetaxel, ARPI (alone or in combination) or with radiation therapy on the primary tumor in combination with ADT within normal clinical practice or expanded access programs initiated between January 2015 and December 2027.\n3. availability of inpatient and\u002For outpatient medical records for clinical data collection\n\nExclusion Criteria:\n\n1. histological diagnosis other than adenocarcinoma\n2. patients who have received multiple lines of ADT for mCSPC\n3. patients who have received docetaxel or ARTA for metastatic castration-resistant disease","MALE",{"count":132,"type":133},3000,"ESTIMATED","5 Years","OBSERVATIONAL","The aim of this observational study is to evaluate the clinical outcomes of treatment with docetaxel, ARTA (alone or in combination) or with radiotherapy on the primary tumor for mCSPC, in an unselected population, in clinical practice",[138,139,140],"Prostate Cancer","Hormone Sensitive Prostate Cancer","Metastatic Tumor","2024-06-24",{"date":143,"type":144},"2024-06-25","ACTUAL",{"date":146,"type":144},"2016-12-16",{"date":148,"type":133},"2028-12",{"name":5,"class":6},3]